Literature DB >> 22278840

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.

Krishna Pandey1, V N R Das, Dharmendra Singh, Sushmita Das, C S Lal, N Verma, S Bimal, R K Topno, N A Siddiqui, R B Verma, P K Sinha, Pradeep Das.   

Abstract

Post kala-azar dermal leishmaniasis (PKDL) is a skin manifestation that usually develops after treatment of visceral leishmaniasis (VL), a major public health problem in India. The diagnosis and management of PKDL is complex. This is the first case report from India in which PKDL occurred after paromomycin treatment for VL in an Indian patient.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22278840      PMCID： PMC3318524          DOI： 10.1128/JCM.05966-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  5 in total

1.  Treatment of post-kala-azar dermal leishmaniasis.

Authors:  S Singh; S Sundar
Journal:  Int J Dermatol       Date:  1995-09       Impact factor: 2.736

2.  Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  P Salotra; G Sreenivas; G P Pogue; N Lee; H L Nakhasi; V Ramesh; N S Negi
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.

Authors:  E E Zijlstra; A M el-Hassan
Journal:  Trans R Soc Trop Med Hyg       Date:  2001-04       Impact factor: 2.184

4.  Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Authors:  Vidya Nand Rabi Das; Krishna Pandey; Neena Verma; Chandra Shekhar Lal; Sanjeev Bimal; Roshan Kamal Topno; Dharmendra Singh; Niyamat Ali Siddiqui; Rakesh Bihari Verma; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2009-03       Impact factor: 2.345

5.  Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs.

Authors:  Shri Prakash Singh; Siddhivinayak Hirve; M Mamun Huda; Megha Raj Banjara; Narendra Kumar; Dinesh Mondal; Shyam Sundar; Pradeep Das; Chitra Kumar Gurung; Suman Rijal; C P Thakur; Beena Varghese; Axel Kroeger
Journal:  PLoS Negl Trop Dis       Date:  2011-02-08
  5 in total
  16 in total

1.  Comparative evaluation of PCR and imprint smear microscopy analyses of skin biopsy specimens in diagnosis of macular, papular, and mixed papulo-nodular lesions of post-kala-azar dermal leishmaniasis.

Authors:  Neena Verma; Dharmendra Singh; Krishna Pandey; Vidya Nand Rabi Das; Chandra Shekhar Lal; Rakesh Bihari Verma; Prabhat Kumar Sinha; Pradeep Das
Journal:  J Clin Microbiol       Date:  2013-09-25       Impact factor: 5.948

2.  A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.

Authors:  Krishna Pandey; Biplab Pal; Niyamat Ali Siddiqui; Chandra Shekhar Lal; Vahab Ali; Sanjiva Bimal; Ashish Kumar; Neena Verma; Vidya Nand Rabi Das; Shubhankar Kumar Singh; Roshan Kamal Topno; Pradeep Das
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

3.  Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.

Authors:  Shamim Islam; Eben Kenah; Mohammed Ashraful Alam Bhuiyan; Kazi Mizanur Rahman; Brook Goodhew; Chowdhury Mohammad Ghalib; M M Zahid; Masayo Ozaki; M W Rahman; Rashidul Haque; Stephen P Luby; James H Maguire; Diana Martin; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2013-07-01       Impact factor: 2.345

Review 4.  Leishmaniasis: where are we and where are we heading?

Authors:  Santanu Sasidharan; Prakash Saudagar
Journal:  Parasitol Res       Date:  2021-04-07       Impact factor: 2.289

5.  Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Authors:  Viroj Wiwanitkit
Journal:  Ther Clin Risk Manag       Date:  2012-06-22       Impact factor: 2.423

6.  PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.

Authors:  Swagata Ganguly; Pabitra Saha; Moytrey Chatterjee; Surajit Roy; Tamal Kanti Ghosh; Subhasish K Guha; Pratip K Kundu; Dilip K Bera; Nandita Basu; Ardhendu K Maji
Journal:  PLoS Negl Trop Dis       Date:  2015-10-20

Review 7.  Post kala-azar dermal leishmaniasis: an unresolved mystery.

Authors:  Debanjan Mukhopadhyay; Jane E Dalton; Paul M Kaye; Mitali Chatterjee
Journal:  Trends Parasitol       Date:  2014-01-02

8.  Mucocutaneous Leishmaniasis/HIV Coinfection Presented as a Diffuse Desquamative Rash.

Authors:  Guilherme Almeida Rosa da Silva; Daniel Sugui; Rafael Fernandes Nunes; Karime de Azevedo; Marcelo de Azevedo; Alexandre Marques; Carlos Martins; Fernando Raphael de Almeida Ferry
Journal:  Case Rep Infect Dis       Date:  2014-12-08

Review 9.  The immunology of post-kala-azar dermal leishmaniasis (PKDL).

Authors:  Eduard E Zijlstra
Journal:  Parasit Vectors       Date:  2016-08-23       Impact factor: 3.876

10.  Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (FungisomeTM) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy.

Authors:  Rama Prosad Goswami; Mehebubar Rahman; Sukhen Das; Santanu Kumar Tripathi; Rudra Prosad Goswami
Journal:  Am J Trop Med Hyg       Date:  2020-05-07       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.